Brief: Lantern Pharma Completes FDA Type C Meeting On Pediatric CNS Cancer Trial
03/09/2025 14:53
Sept 3 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA ANNOUNCES COMPLETION OF TYPE C MEETING WITH FDA, PROVIDING CLARITY ON REGULATORY PATHWAY FOR PEDIATRIC CNS CANCER TRIAL LANTERN PHARMA INC - FDA CONFIRMS POTENTIAL INCORPORATION OF SPIRONOLACTONE AS COMBINATION AGENT IN TRIAL LANTERN PHARMA INC - PLANS IND AMENDMENT SUBMISSION & TRIAL INITIATION FOR PEDIATRIC CNS CANCER TRIAL IN Q1 2026 Source text: ID:nBwbG7HD1a Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview